Incyte Corp (INCY)

120.49
NASDAQ : Health Care
Prev Close 120.18
Day Low/High 119.16 / 120.85
52 Wk Low/High 60.30 / 125.49
Avg Volume 1.34M
Exchange NASDAQ
Shares Outstanding 189.41M
Market Cap 22.76B
P/E Ratio 222.56
Div & Yield N.A. (N.A)

Latest News

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CRVL, INCY, WHLR Downgrades: BABA, FLO, ITT, TPX Initiations: AUXO Read on to get TheStreet Quant Ratings' detailed report:

Http://www.agenusbio.com

Http://www.agenusbio.com

Incyte Corporation (Nasdaq:INCY) and Agenus Inc. (Nasdaq:AGEN) announced today that the companies have amended the License, Development and Commercialization Agreement that was originally entered into January 9, 2015.

Incyte Reports 2016 Fourth-Quarter And Year-End Financial Results, Provides 2017 Financial Guidance And Updates On Key Clinical Programs

Incyte Reports 2016 Fourth-Quarter And Year-End Financial Results, Provides 2017 Financial Guidance And Updates On Key Clinical Programs

Incyte Corporation (Nasdaq:INCY) today reports 2016 fourth-quarter and year-end financial results, highlighting strong revenue growth driven by increased sales of Jakafi ® (ruxolitinib) in the U.

5 Things You Must Know Before the Market Opens Tuesday

5 Things You Must Know Before the Market Opens Tuesday

U.S. stock futures are declining Tuesday while European and Asian shares trade mixed ahead of congressional testimony from Federal Reserve Chair Janet Yellen.

Week Ahead: Federal Reserve Officials, Major Economic Data to Drive Market Movement

Week Ahead: Federal Reserve Officials, Major Economic Data to Drive Market Movement

Fed Chair Janet Yellen will give her two-day semiannual monetary policy testimony, while major economic data will drive markets.

Incyte And Calithera Biosciences Announce Global Collaboration To Develop And Commercialize CB-1158, A First-in-class, Small Molecule Arginase Inhibitor

Incyte And Calithera Biosciences Announce Global Collaboration To Develop And Commercialize CB-1158, A First-in-class, Small Molecule Arginase Inhibitor

Incyte Corporation (NASDAQ:INCY) and Calithera Biosciences, Inc. (NASDAQ:CALA) announce today that the companies have entered into a global collaboration and license agreement for the research, development and...

Incyte To Report Fourth Quarter And Year-End Financial Results

Incyte To Report Fourth Quarter And Year-End Financial Results

Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its fourth quarter and year end 2016 financial results conference call and webcast for 10:00 a.

4 Biotech Names That Could Be M&A Targets

4 Biotech Names That Could Be M&A Targets

Animal health and oncology deal activity is heating up in 2017.

Monday's Sights, Sounds and Biotech Buzz From the J.P. Morgan Healthcare Conference

Monday's Sights, Sounds and Biotech Buzz From the J.P. Morgan Healthcare Conference

The $5.2 billion takeout of Ariad Pharma was the biggest news from the closely followed healthcare conference.

Merck Cancer Drug Test Sends Incyte Shares Higher

Merck Cancer Drug Test Sends Incyte Shares Higher

The companies will study epacadostat in tandem with Merck's Keytruda in patients with non-small cell lung, renal, bladder and head and neck cancers.

Biotech Stocks Surge Monday Amid Flurry of Deal Activity

Biotech Stocks Surge Monday Amid Flurry of Deal Activity

Deals, though, weren't the only mover of share prices.

Incyte And Merck To Advance Clinical Development Program Investigating The Combination Of Epacadostat With KEYTRUDA® (pembrolizumab)

Incyte And Merck To Advance Clinical Development Program Investigating The Combination Of Epacadostat With KEYTRUDA® (pembrolizumab)

Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the decision to advance the clinical development program investigating the combination of...

What Biotech Investors Can Expect From the J.P. Morgan Health Care Conference 2017

What Biotech Investors Can Expect From the J.P. Morgan Health Care Conference 2017

Every January at 'JPM,' investors take the pulse of the biotech industry for the coming year.

Biotech Should Witness M&A's Return in 2017

Biotech Should Witness M&A's Return in 2017

Drug giants with money to spend and a friendlier regulatory environment should spur deals.

Incyte Announces First Patient Treated In Pivotal Clinical Trial Program For Ruxolitinib (Jakafi®) In Graft-versus-Host Disease

Incyte Announces First Patient Treated In Pivotal Clinical Trial Program For Ruxolitinib (Jakafi®) In Graft-versus-Host Disease

Incyte Corporation (Nasdaq:INCY) today announced that the first patient has been treated in the REACH-1 pivotal Phase 2 trial evaluating ruxolitinib (Jakafi ®) in combination with corticosteroids for the treatment of...

Incyte To Present At Upcoming Investor Conference

Incyte To Present At Upcoming Investor Conference

Incyte Corporation (Nasdaq:INCY) announced today that it will present at the 35 th Annual J.

Pooled Analysis Of Five-Year Data From Two Phase 3 Studies Further Supports Overall Survival Advantage Observed In Patients With Myelofibrosis Treated With Jakafi® (ruxolitinib)

Pooled Analysis Of Five-Year Data From Two Phase 3 Studies Further Supports Overall Survival Advantage Observed In Patients With Myelofibrosis Treated With Jakafi® (ruxolitinib)

Incyte Corporation (Nasdaq:INCY) today announces an exploratory pooled analysis of data from the five-year follow-up of the Phase 3 COMFORT-I and COMFORT-II trials which further supports previously published overall...

2 Small-Cap Biotech Buyout Targets

2 Small-Cap Biotech Buyout Targets

With the election resolved, biotech could be ripe for consolidation.

Get Excited About Incyte

Get Excited About Incyte

Prices have marched their way all the way back up to the bottom end of key resistance.

Hey Gilead, Stop Developing Drugs and Start Buying Biotech Companies -- Now!

Hey Gilead, Stop Developing Drugs and Start Buying Biotech Companies -- Now!

For as much as we love and respect you, Gilead, the current situation is unacceptable. The once great and mighty biotech Gilead cannot trade at a 6x forward earnings multiple!

Six Thoughts on President Trump and the Durability of the Biotech Stock Rally

Six Thoughts on President Trump and the Durability of the Biotech Stock Rally

Investors have convinced themselves that President Donald Trump is going to make drug stocks great again. Will it last?

Incyte Becomes #40 Most Shorted Nasdaq 100 Component, Replacing Stericycle

Incyte Becomes #40 Most Shorted Nasdaq 100 Component, Replacing Stericycle

The most recent short interest data has been released for the 10/31/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Gilead Sciences' Next Challenge to Incyte's Myelofibrosis Drug Dominance

Gilead Sciences' Next Challenge to Incyte's Myelofibrosis Drug Dominance

Gilead Sciences is nearing the completion of two phase III studies of the Jak inhibitor momelotinib in myelofibrosis, a disease affecting bone marrow.

More Than 20 Abstracts Highlighting Data From Incyte's Portfolio Accepted For Presentation At The 58th Annual ASH Meeting

More Than 20 Abstracts Highlighting Data From Incyte's Portfolio Accepted For Presentation At The 58th Annual ASH Meeting

Incyte Corporation (Nasdaq: INCY) announces that more than 20 abstracts including data from its ongoing clinical development program for Jakafi ® (ruxolitinib) and its small molecule development programs targeting...

Why Incyte's Shares Could Soon Hit $100

Why Incyte's Shares Could Soon Hit $100

The drug company reported strong earnings.

Incyte To Present At Upcoming Investor Conference

Incyte To Present At Upcoming Investor Conference

Incyte Corporation (Nasdaq:INCY) announced today that it will present at the 28 th Annual Piper Jaffray Healthcare Conference on Tuesday, November 29, 2016 at 11:30 am (EST) in New York.